在强化化疗与局限放疗时代,无复发的霍奇金淋巴瘤幸存者医疗使用增加持续至10年
研究基于瑞典全国登记数据,纳入2000-2009年诊断的1017例18-60岁霍奇金淋巴瘤幸存者及4031例匹配对照,评估诊断后第一年至14年间的门诊就诊与住院床日。无复发幸存者门诊就诊率近对照2倍(IRR=1.8,95%CI:1.6-2.0),住院床日率超3倍(IRR=3.6,95%CI:2.7-4.7),化疗疗程较多者医疗使用更高。
要点
- 无复发霍奇金淋巴瘤幸存者门诊就诊率近对照2倍(IRR=1.8,95%CI:1.6-2.0),持续至诊断后10年。
- 住院床日率超对照3倍(IRR=3.6,95%CI:2.7-4.7),持续至诊断后4年。
- 6-8疗程化疗者较2-4疗程+放疗者门诊就诊率更高(IRR=1.4,95%CI:1.1-1.7)。
核心结论
- 当代治疗尤其是化疗与霍奇金淋巴瘤幸存者诊断后第一个十年内医疗使用增加相关。
- 就诊原因反映多种疾病,提示除特定筛查项目外需要广泛的个体化照护。
研究设计与样本
- 基于瑞典全国登记数据的队列研究,识别2000-2009年诊断的1017例18-60岁(中位32岁)霍奇金淋巴瘤幸存者及4031例按年龄、性别、日历年匹配的对照。
- 采用负二项回归估计诊断后第一年至14年(至2013年)的门诊就诊与住院床日发生率比(IRR)及95%CI,按治疗亚组分析并考虑无复发时间。
- 霍奇金淋巴瘤计划性门诊就诊被排除。
主要发现
- 门诊就诊率近对照2倍(IRR=1.8,95%CI:1.6-2.0),升高持续至诊断后10年。
- 无复发幸存者住院床日率超对照3倍(IRR=3.6,95%CI:2.7-4.7),升高持续至诊断后4年。
- 需6-8疗程化疗者较2-4疗程+放疗者门诊就诊率更高(IRR=1.4,95%CI:1.1-1.7),住院床日率更高(IRR=4.7,95%CI:2.9-7.8)。
- 既往少报的医疗使用过多原因包括胸痛、角膜炎、哮喘、糖尿病和抑郁。
临床怎么用
- 作者认为就诊原因反映多种疾病,提示除特定筛查项目外需要广泛的个体化照护。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With today's excellent cure rates for Hodgkin lymphoma (HL), the number of long-term survivors is increasing. This study aims to provide a global assessment of late adverse effects for working-age HL survivors treated with contemporary protocols (combination chemotherapy and limited radiotherapy). From Swedish nationwide registers we identified 1017 HL survivors diagnosed in 2000-2009, aged 18-60 years (median 32) and surviving at least one year post-diagnosis, and 4031 age-, sex-, and calendar-year-matched population comparators. Incidence rate ratios (IRR) and 95% confidence intervals (95%CI) for outpatient visits and inpatient bed-days after the first year up to 14 years post-diagnosis (through 2013) were estimated across treatment subgroups, considering relapse-free time and using negative binomial regression. Scheduled outpatient visits for HL were excluded. The rate of outpatient visits was nearly double (IRR = 1.8, 95%CI: 1.6-2.0) that among comparators and higher rates persisted up to 10 years post-diagnosis. The rate of inpatient bed-days among relapse-free survivors was more than three-fold (IRR = 3.6, 95%CI: 2.7-4.7) that of comparators and the increase persisted up to four years post-diagnosis. Patients requiring 6-8 chemotherapy courses had higher rates of outpatient visits (IRR = 1.4, 95%CI: 1.1-1.7) and bed-days (IRR = 4.7, 95%CI: 2.9-7.8) than patients treated with 2-4 courses + radiotherapy. Previously seldom reported reasons for the excess healthcare use included chest pain, keratitis, asthma, diabetes mellitus, and depression. Contemporary treatment, chemotherapy in particular, was associated with excess healthcare use among HL survivors during the first decade postdiagnosis. The reasons for healthcare visits reflected a wide range of disorders, indicating the need of broad individualized care in addition to specific screening programs.
引用
- Glimelius I, Eloranta S, Ekberg S, et al. Increased healthcare use up to 10 years among relapse-free Hodgkin lymphoma survivors in the era of intensified chemotherapy and limited radiotherapy. Am J Hematol. 2017. PMID: 28006849. doi:10.1002/ajh.24623
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。